Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Splenic Marginal Zone in Children Is Characterized by a Subpopulation of CD27-Negative, Lowly IGHV-Mutated B Cells. | Front Immunol | 2022 | 35154145 | PubTator, text mining | PubMed |
| Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis. | Cancer Gene Ther | 2022 | 35145272 | PubTator, text mining | PubMed |
| Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia. | BMC Cancer | 2022 | 35123433 | PubTator, text mining | PubMed |
| Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. | Mol Cancer | 2022 | 35120522 | PubTator, text mining | PubMed |
| Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes. | BMC Cancer | 2022 | 35114947 | PubTator, text mining | PubMed |
| Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. | Cell Rep | 2022 | 35114110 | PubTator, text mining | PubMed |
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. | Adv Hematol | 2022 | 35103064 | PubTator, text mining | PubMed |
| Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients. | Biomark Insights | 2022 | 35095271 | PubTator, text mining | PubMed |
| Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia. | Semin Cancer Biol | 2022 | 35090979 | PubTator, text mining | PubMed |
| Identification of a ZC3H12D-regulated competing endogenous RNA network for prognosis of lung adenocarcinoma at single-cell level. | BMC Cancer | 2022 | 35090416 | PubTator, text mining | PubMed |
| CLL-IPI applied in Binet A CLL: a nationwide cohort study. | Blood Adv | 2022 | 35090168 | PubTator, text mining | PubMed |
| Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. | Blood Adv | 2022 | 35086141 | PubTator, text mining | PubMed |
| Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica. | Cancer Rep (Hoboken) | 2022 | 35075812 | PubTator, text mining | PubMed |
| Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. | Blood Adv | 2022 | 35073571 | PubTator, text mining | PubMed |
| Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic. | Curr Oncol Rep | 2022 | 35061199 | PubTator, text mining | PubMed |
| Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection. | Cancers (Basel) | 2022 | 35053445 | PubTator, text mining | PubMed |
| Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. | Healthcare (Basel) | 2022 | 35052318 | PubTator, text mining | PubMed |
| InterTADs: integration of multi-omics data on topologically associated domains, application to chronic lymphocytic leukemia. | NAR Genom Bioinform | 2022 | 35047813 | PubTator, text mining | PubMed |
| Identification of CD105 (endoglin) as novel risk marker in CLL. | Ann Hematol | 2022 | 35044512 | PubTator, text mining | PubMed |
| Deep learning model of somatic hypermutation reveals importance of sequence context beyond hotspot targeting. | iScience | 2022 | 35036866 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=35